Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
625.00    0.00 (0.00%)
Bid:
618.00
Ask:
621.00
Spread: 3.00 (0.485%)
Market Cap: £756.31m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Director/PDMR Shareholding

5 May 2016 09:22

RNS Number : 3454X
Oxford Biomedica PLC
05 May 2016
 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

1

Issuer

Oxford BioMedica PLC

2

Reason for notification

Notification relates to DTR 3.1.2R

3

Name of PDMR

Martin Diggle

4

Connected person

Notification relates to following connected persons:

Vulpes Life Sciences Fund

5

Notification in respect of

Notification in respect of holdings of persons in 4 above

6

Description of shares

Oxford BioMedica PLC ordinary shares of 1p each

7

Name of registered shareholders and number of shares

Vulpes Life Sciences Fund - 475,705,311 shares

8

Nature of transaction

Acquisition

9

Number of shares acquired

 

Vulpes Life Sciences Fund - 44,689 shares

 

10

Percentage of issued class acquired

Vulpes Life Sciences Fund - 0.01%

 

11

Shares disposed

N/A

 

12

Percentage of issued class disposed

N/A

 

13/14

Price per share of transactions, and date

Vulpes Life Sciences Fund

44,689 shares @ £0.057 , 04 May 2016

 

15

Total holding following notification and total percentage holding following notification

Vulpes Life Sciences Fund - 475,750,000 shares

17.60%

16

Date issuer informed

05 May 2016

23

Any additional information

None

24

Contact name and telephone number

T. Watts, Chief Financial Officer

Oxford BioMedica

+44 (0)1865 783000

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGIGDUGDGBGLU
Date   Source Headline
30th Apr 20191:35 pmRNSOxford Biomedica to present at the ASGCT
30th Apr 20191:15 pmRNSAxovant doses second cohort of AXO-Lenti-PD
25th Apr 20193:38 pmRNSDirector Dealings / Market Share Purchase
23rd Apr 20191:47 pmRNSDeferred Bonus Plan and LTIP Option Grants
23rd Apr 201911:38 amRNSDirector Dealings / Market Share Transactions
18th Apr 20195:33 pmRNSExercise of warrants
18th Apr 20197:00 amRNSAnnual Report and Accounts & AGM Notification
1st Apr 201911:40 amRNSTotal Voting Rights
26th Mar 201912:57 pmRNSDirector Dealings / Market Share Purchase
26th Mar 20198:25 amRNSJapanese approval of Kymriah® (tisagenlecleucel)
14th Mar 20197:00 amRNSPreliminary Results
12th Mar 20197:00 amRNSOXB announces R&D collaboration with Microsoft
11th Mar 201910:38 amRNSAxovant's update on Phase 2 trial of AXO-Lenti-PD
1st Mar 20199:30 amRNSTotal Voting Rights
25th Feb 201912:23 pmRNSDirector Dealings / Market Share Purchase
8th Feb 20197:00 amRNSNotice of Results
7th Feb 201911:49 amRNSDirector/PDMR Shareholding
7th Feb 20199:22 amRNSUpdate on programmes outlicensed to Sanofi
6th Feb 201911:00 amRNSDirector Dealings / Market Share Transactions
5th Feb 201910:22 amRNSDirector Dealings / Market Share Purchase
1st Feb 201910:00 amRNSTotal Voting Rights
24th Jan 201911:20 amRNSDirector Dealings / Market Share Purchase
3rd Jan 201912:20 pmRNSBlock listing Interim Review
2nd Jan 201910:17 amRNSTotal Voting Rights
21st Dec 20181:16 pmRNSDirector Dealings / Market Share Purchase
6th Dec 20184:11 pmRNSAxovant FDA meeting feedback
3rd Dec 20189:53 amRNSTotal Voting Rights
3rd Dec 20187:00 amRNSLonger term Kymriah efficacy and safety data
23rd Nov 201810:41 amRNSDirector Dealings
23rd Nov 20187:00 amRNSOxford Biomedica form digital framework initiative
9th Nov 20187:00 amRNSBlock listing application
1st Nov 20182:41 pmRNSTotal Voting Rights
25th Oct 20187:00 amRNSAxovant Doses First Patient with AXO-Lenti-PD
22nd Oct 20184:39 pmRNSDirector Dealings / Market Share Purchase
5th Oct 20187:00 amRNSDetails of alliance with Orchard Therapeutics
1st Oct 20189:41 amRNSTotal Voting Rights
24th Sep 201812:20 pmRNSDirector/PDMR Shareholding
20th Sep 201810:57 amEQSHardman & Co Research: Oxford BioMedica (OXB): Partnering strategy delivering profitability
13th Sep 20187:00 amRNSOxford BioMedica Interim Results
13th Sep 20187:00 amRNSOxford BioMedica further capacity expansion
3rd Sep 20189:18 amRNSTotal Voting Rights
28th Aug 20187:00 amRNSKymriah® receives European Commission Approval
22nd Aug 201811:58 amRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSRNS notice of results OXB
14th Aug 20187:15 amEQSHardman & Co Research: Oxford BioMedica (OXB): Risk-sharing in cystic fibrosis gene-therapy
13th Aug 201810:55 amRNSDirector/PDMR Shareholding
13th Aug 201810:48 amRNSDirector/PDMR Shareholding
10th Aug 201811:39 amRNSPDMR Dealings / Market Share Sale
10th Aug 201811:36 amRNSDirector Dealings / Market Share Sale and Purchase
8th Aug 20182:45 pmRNSShare Options and LTIPs Granted

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.